



## UvA-DARE (Digital Academic Repository)

### Fusobacterium nucleatum septicemia and portal vein thrombosis [brief report]

Bultink, I.E.M.; Dorigo-Zetsma, J.W.; Koopman, M.G.; Kuijper, E.J.

**DOI**

[10.1086/517785](https://doi.org/10.1086/517785)

**Publication date**

1999

**Published in**

Clinical infectious diseases

[Link to publication](#)

**Citation for published version (APA):**

Bultink, I. E. M., Dorigo-Zetsma, J. W., Koopman, M. G., & Kuijper, E. J. (1999). Fusobacterium nucleatum septicemia and portal vein thrombosis [brief report]. *Clinical infectious diseases*, 28, 1325-1326. <https://doi.org/10.1086/517785>

**General rights**

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

**Disclaimer/Complaints regulations**

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

**Table 1.** Summary of results of liver function tests for a patient with acute hepatitis A who had received preexposure inactivated hepatitis A virus vaccine.

Finding	Date of test					
	13/7/98	14/7/98	16/7/98	20/7/98	22/7/98	11/8/98
Total protein level (g/L)	64	63	65	74	78	76
Albumin level (g/L)	33	32	31	34	35	43
Total bilirubin level ( $\mu\text{mol/L}$ )	50	57	81	86	96	14
SAP level (U/L)	356	284	280	489	470	114
ALT level (U/L)	2,273	2,037	2,097	427	271	54
AST level (U/L)	3,247	1,762	1,541	186	114	35

NOTE. ALT = alanine aminotransferase; AST = aspartate aminotransferase; SAP = serum alkaline phosphatase.

A seroconversion failure rate of 0.1% has been found, and these failures occurred for smokers, alcoholics, immunocompromised persons, and patients with concurrent illness with hepatitis C or B (D. R. Nalin, unpublished data). Our patient did not have any of the risk factors associated with low rates of seroconversion. One consideration is the use of inhaled steroids by our patient, which may have been associated with the lack of seroconversion.

#### Asok Kurup, Lam Mun San, and Wong Sin Yew

Department of Infectious Diseases, Communicable Disease Centre, Singapore

#### References

1. Werzberger A, Kuster B, Nalin D. Six years' follow-up after hepatitis A vaccination. *N Engl J Med* 1999;338:1160.
2. Werzberger A, Mensch B, Kuster B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. *N Engl J Med* 1992;327:453-7.
3. McMahon BJ, Beller M, Williams J, Schloss M, Taniguchi H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. *Arch Pediatr Adolesc Med* 1996;150:733-9.
4. Ellerbeck E, Lewis J, Midhun K, et al. Safety and immunogenicity of an inactivated hepatitis A virus vaccine. *Viral hepatitis and liver disease [abstracts].* In: Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: contemporary issues and future prospects. Baltimore: Williams & Wilkins, 1991:91-3.
5. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 1996;45(RR-15):1-30.
6. Innis BL, Snihan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. *JAMA* 1994;271:1328-34.
7. Daniel S, Yaffa A, Ruzh A, et al. Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison of administration of immune globulin. *J Hepatol* 1993;18(suppl 2):S32-7.
8. Isre GR, Hopkins RS. An outbreak of foodborne hepatitis A showing a relationship between dose and incubation period. *Am J Public Health* 1975;75:280-1.

#### *Fusobacterium nucleatum* Septicemia and Portal Vein Thrombosis

Like *Fusobacterium necrophorum*, *Fusobacterium nucleatum* is capable of causing thrombophlebitis of the internal jugular vein in previously healthy young adults, usually following pharyngotonsillar infection [1, 2]. Although complications of venous thrombosis at various locations have been described in cases of *F. nucleatum* septicemia, portal vein thrombosis has never been reported. We describe a patient with *F. nucleatum* septicemia and portal vein thrombosis.

A 23-year-old man was hospitalized in February 1995 because of a 14-day history of abdominal pain, vomiting, rigors, and fever (temperature  $>40^{\circ}\text{C}$ ). Five weeks before the onset of symptoms, he was treated with fenicillin for oropharyngeal infection. Physical examination was unremarkable. Laboratory tests showed an increased WBC count of  $16.4 \times 10^9/\text{L}$ , with 80% neutrophils and a left shift, and toxic changes. Liver function tests revealed mild elevations in levels of transaminases (aspartate aminotransferase, 61 U/L; alanine aminotransferase, 113 U/L), alkaline phosphatase (192 U/L), and  $\gamma$ -glutamyl transferase (144 U/L), and a normal bilirubin level. Ultrasonographic examination of the abdomen demonstrated hepatosplenomegaly.

After 5 days of imipenem treatment (2 g/d), his symptoms abated, and the patient was discharged. No pathogens were isolated from cultures of blood, urine, and stool. Fifteen days later, he was readmitted with fever, abdominal pain, jaundice, and respiratory distress. Ultrasonographic examination by means of the pulsed duplex Doppler technique demonstrated hepatosplenomegaly, thrombosis of the portal vein (which was enlarged), and extensive collateral vessels in the hepatic hilus. Imipenem and heparin were

Reprints or correspondence: Dr. Irene E. M. Bulink, Department of Internal Medicine, Academic Medical Center of the University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands (wjdb@worldonline.nl).

*Clinical Infectious Diseases* 1999;28:1325-6

© 1999 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/99/2806-0027\$03.00



**Figure 1.** CT scan (with intravenous contrast) of the abdomen of a patient with *Fusobacterium nucleatum* septicemia and portal vein thrombosis; the scan shows splenomegaly and collateral vessels (arrow) in the hilum of the liver and spleen. The portal vein is not filled with contrast because of thrombosis.

administered. The patient's condition worsened, and he was transferred to the Academic Medical Center of the University of Amsterdam.

At the time of physical examination, the patient was ill-appearing; findings included normal vital signs, hepatosplenomegaly, and temporary pericardial and pleural friction rubs. Repeat CT of the abdomen (figure 1) showed portal vein thrombosis and an increasing spleen size (maximum span, 25 cm). Upper gastrointestinal endoscopy demonstrated esophageal varices. Laboratory investigations showed no autoimmune or systemic disease or hypercoagulable state. Administration of the antithrombotic and heparin was stopped. After 5 days, fever and rigors returned, accompanied by leukocytosis. Of 14 blood specimens for culture that were obtained in his febrile phase, five became positive for *F. nucleatum* on days 7–10; the organism was susceptible to penicillin and meropenem but resistant to erythromycin (findings were confirmed by the Laboratory for Bacterial Identification of the National Institute for Health and Environment, Bilthoven, the Netherlands). A 6-week course of therapy with intravenous penicillin (12 million U/d) resulted in recovery, although portal vein thrombosis persisted.

Our patient had a clinical syndrome of fever, portal vein thrombosis, and transient pleuropericarditis. Blood cultures finally became positive for *F. nucleatum* after prolonged incubation (7–10 days) and prolonged subculturing (3 days). We considered two hypotheses for the pathogenesis of his clinical syndrome. First, preexisting portal vein thrombosis may be infected with *F. nuclea-*

*tum* from an unknown source. Second, oropharyngeal infection 5 weeks before the onset of symptoms may be followed by *F. nucleatum* septicemia resulting in thrombophlebitis and thrombosis of the portal vein.

One argument in favor of the second hypothesis is the changing image of the portal vein at repeated ultrasonographic examinations. First, an echogenic thrombus within a dilated portal vein and the lack of variation in the diameter of the portal vein with respiration were demonstrated, findings highly indicative of acute portal vein occlusion [3]; 2 months later, the diameter of the portal vein was very small, as is the case with longstanding thrombus [4]. Another argument for the second hypothesis concerns septicemia due to *F. nucleatum*. Complications of venous thrombosis at various locations have been described in cases of fusobacterium septicemia [2, 5]. The ability of virulent *Fusobacterium* strains to cause thrombophlebitis and metastatic abscesses can probably be ascribed to the lipid A component of the lipopolysaccharide endotoxin of *Fusobacterium* species. This virulence factor has been shown to be capable of in vivo activation of the human Hageman factor and the intrinsic pathway of coagulation [6]. Aggregation of platelets by *F. necrophorum* has been demonstrated in vitro and is also a virulence property [7, 8].

**Irene E. M. Bultink, J. Wendelien Dorigo-Zetsma,  
Marion G. Koopman, and Ed J. Kuijper**

*Departments of Internal Medicine and Medical Microbiology, Academic Medical Center of the University of Amsterdam, Amsterdam, and Laboratory for Bacterial Identification of the National Institute for Health and Environment, Bilthoven, the Netherlands*

#### References

1. Henry S, DeMaria A, McCabe WR, et al. Bacteremia due to *Fusobacterium* species. *Am J Med* 19 3;75:225–31.
2. Benne KW, Eley A. Fusobacteremia: new taxonomy and related diseases. *J Med Microbiol* 1993;39:246–54.
3. Schwert WB. Portal vein thrombosis: real-time sonographic demonstration and follow-up. *Gastrointest Radiol* 19 6;11:312–8.
4. Miller VE, Berland LL. Pulsed Doppler duplex sonography and CT of portal vein thrombosis. *Am J Roentgenol* 19 5;145:73–6.
5. Sinave CP, Hardy GJ, Fardy PW. The Lemierre syndrome: suppurative thrombophlebitis of the internal jugular vein secondary to oropharyngeal infection. *Medicine (Baltimore)* 19 9;168:85–94.
6. Bjornson HS. Activation of Hageman factor by lipopolysaccharides of *Bacteroides fragilis*, *Bacteroides vulgatus* and *Fusobacterium mortiferum*. *Rev Infect Dis* 19 4;6(suppl 1):S30–3.
7. Forrester LJ, Campbell BJ, Berg JN, et al. Aggregation of platelets by *Fusobacterium necrophorum*. *J Clin Microbiol* 19 5;22:245–9.
8. Kanoe M, Yamanaka M, Inoue M. Efforts of *Fusobacterium necrophorum* on the mesenteric microcirculation of guinea pigs. *Med Microbiol Immunol* 19 9;178:99–104.